Gene therapy, a technique that is revolutionizing the treatment of multiple genetic conditions, including eye and muscle ...

The vector includes a cytomegalovirus (CMV ... USH2A is a major focus, with two oligonucleotide candidates advancing in the ...

A recent study demonstrated the potential of gene therapy to restore motor capacity in an ultra-rare disease, megalencephalic ...

Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...

Cell And Gene Therapy Market Size and ForecastThe global cell and gene therapy market is projected to witness significant ...

Gene therapies are a revolution in medicine but over the past few years, companies developing them for many serious ...

To help improve gene therapy, a multidisciplinary team has generated a comprehensive atlas that researchers can use to select ...

A recent study led by the UAB demonstrates the potential of gene therapy to restore motor capacity in an ultra-rare disease, ...

A recent study led by the UAB demonstrates the potential of gene therapy to restore motor capacity in an ultra-rare disease, ...

Variant SAS and the Rare Ocular Diseases Center at the University of Campania Luigi Vanvitelli (UCLV) have received positive feedback from the EMA for VAR-002, a recombinant AAV vector gene therapy ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

Variant, a company dedicated to developing innovative treatments for orphan inherited eye diseases, and the Rare Ocular Diseases Center at the University of Campania Luigi Vanvitelli (UCLV) in Naples ...